• 1
    Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819823.
  • 2
    Francis GS, Benedict C., Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 17241729.
  • 3
    Packer M., Lee WH, Kessler PD, et al. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987;75:IV8092.
  • 4
    Gottlieb SS, Kukin ML, Ahern D., Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:15341539.
  • 5
    Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol 2001;37:386391.
  • 6
    Hulsmann M., Berger R., Sturm B., et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J 2002;23:886891.
  • 7
    Hulsmann M., Stanek B., Frey B., et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998;32:16951700.
  • 8
    Pacher R., Stanek B., Hulsmann M., et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633641.
  • 9
    Stanek B., Frey B., Hulsmann M., et al. Validation of big endothelin plasma levels compared with established neurohumoral markers in patients with severe chronic heart failure. Transplant Proc 1997;29:595596.
  • 10
    Stanek B., Frey B., Berger R., et al. Value of sequential big endothelin plasma concentrations to predict rapid worsening of chronic heart failure. Transplant Proc 1999;31:155157.
  • 11
    Frey B., Pacher R., Locker G., et al. Prognostic value of hemodynamic vs big endothelin measurements during long-term IV therapy in advanced heart failure patients. Chest 2000; 117: 17131719.
  • 12
    Ware WA, Lund DD, Subieta AR, Schmid PG. Sympathetic activation in dogs with congestive heart failure caused by chronic mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 1990;197:14751481.
  • 13
    Koch J., Pedersen HD, Jensen AL, et al. Activation of the renin-angiotensin system in dogs with asymptomatic and symptomatic dilated cardiomyopathy. Res Vet Sci 1995;59:172175.
  • 14
    Tidholm A., Haggstrom J., Hansson K. Effects of dilated cardiomyopathy on the renin-angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormone concentrations in dogs. Am J Vet Res 2001;62:961967.
  • 15
    Vollmar AM, Montag C., Preusser U., et al. Atrial natriuretic peptide and plasma volume of dogs suffering from heart failure or dehydration. J Vet Med 1994;41:548557.
  • 16
    Chetboul V., Tessier-Vetzel D., Escriou C., et al. Diagnostic potential of natriuretic peptides in the occult phase of golden retriever muscular dystrophy cardiomyopathy. J Vet Intern Med 2004; 18:845850.
  • 17
    Prosek R., Sisson DD, Oyama MA, et al. Plasma endothelin-1 immunoreactivity in normal dogs and dogs with acquired heart disease. J Vet Intern Med 2004; 18:840844.
  • 18
    Giannessi D., Del Ry S., Vitale RL. The role of endothelins and their receptors in heart failure. Pharmacol Res 2001;43:111126.
  • 19
    Wei CM, Lerman A., Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89:15801586.
  • 20
    Thomas WP, Gaber CE, Jacobs GJ, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in dogs and cats. J Vet Intern Med 1993;7:247252.
  • 21
    Sahn DJ, DeMario A., Kisslo JA, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978;58:10721083.
  • 22
    O'Sullivan ML. Echocardiographic Assessment of Diastolic Function and Neurohormonal Activation in Doberman Pinschers with Dilated Cardiomyopathy. Guelph, ON, Canada: University of Guelph; 2003: Thesis.
  • 23
    Oikawa S., Imai M., Inuzuka C., et al. Structure of dog and rabbit precursors of atrial natriuretic polypeptides deduced from nucleotide sequence of cloned cDNA. Biochem Biophys Res Commun 1985;132:892899.
  • 24
    Steel RGD, Torrie JH, Dickey DA. Analysis of covariance. In: SteelRGD, TorrieJH, DickeyDA, eds. Principles and Procedures of Statistics: A Biometrical Approach. 3rd ed. Boston , MA : McGraw-Hill; 1997: 429458.
  • 25
    Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248254.
  • 26
    Travill CM, Williams TD, Pate P., et al. Haemodynamic and neurohumoral response in heart failure produced by rapid ventricular pacing. Cardiovasc Res 1992;26:783790.
  • 27
    Isnard R., Pousset F., Trochu J., et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000;86:417421.
  • 28
    Benedict CR, Shelton B., Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996; 94: 690697.
  • 29
    Colucci WS, Braunwald E. Pathophysiology of heart failure. In: BraunwaldE., ZipesDP, LibbyP., eds. Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia , PA : WB Saunders; 2001: 503533.
  • 30
    Mizuno Y., Yoshimura M., Yasue H., et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:7277.
  • 31
    Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195203.
  • 32
    Fruhwald FM, Fahrleitner A., Watzinger N., et al. Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. Eur Heart J 1999;20:14151423.
  • 33
    Krum H., Gu A., Wilshire-Clement M., et al. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J 1996;131:337341.
  • 34
    Galatius-Jensen S., Wroblewski H., Emmeluth C., et al. Plasma endothelin in congestive heart failure: Effect of the ACE inhibitor, fosinopril. Cardiovasc Res 1996;32:11481154.
  • 35
    D'Alesandro MM, Gruber DF, Reed HL, et al. Effects of collection methods and storage on the in vitro stability of canine plasma catecholamines. Am J Vet Res 1990;51:257259.
  • 36
    Tan AC, Kloppenborg PW, Benraad TJ. Storage and thawing influence plasma levels of immunoreactive atrial natriuretic peptide. Clin Chim Acta 1990;191:111113.
  • 37
    Nelesen RA, Dimsdale JE, Ziegler MG. Plasma atrial natriuretic peptide is unstable under most storage conditions. Circulation 1992;86:463466.